-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pasithea Therapeutics Further Strengthens Its Scientific Advisory Board With the Appointment of Dr. Merit Cudkowicz
Pasithea Therapeutics Further Strengthens Its Scientific Advisory Board With the Appointment of Dr. Merit Cudkowicz
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases --
MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Merit Cudkowicz to its Scientific Advisory Board ("SAB").
Dr. Cudkowicz is the Chief of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a pioneer in promoting and devising more efficient methods for the development of new therapies for people with neurological disorders such as ALS and is one of the founders and co-directors of the Northeast ALS (NEALS) Consortium, a group of over 130 clinical sites in the United States and Canada dedicated to performing collaborative academic-led clinical trials in ALS. Dr. Cudkowicz is also the Study Chair and Principal Investigator of the HEALEY ALS Platform Trial, a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
"Dr. Cudkowicz's achievements in the research and treatment of ALS are extraordinary and second to none, and her collaborative, cross-field methodology has revolutionized ALS clinical trials. Her knowledge, experience, and forward-thinking approach will be a huge asset to Pasithea as we advance our mission of bringing our alpha-5/beta-1 monoclonal antibody to clinical trials in ALS," said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
"I am honored that my role with the SAB will allow me to work closely with Dr. Steinman and the team at Pasithea on their new program for ALS. Their approach is novel, with preclinical and human post-mortem data supporting a role for alpha-5/beta-1 integrin in the pathophysiology of ALS. The preclinical efficacy data of Pasithea´s monoclonal antibody targeting alpha-5/beta-1 integrin is very encouraging and we will work together to bring this drug to clinical trial for people living with ALS," stated Dr. Cudkowicz.
Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award, the 2017 Forbes Norris Award from the International MND Alliance, the 2017 Pinnacle Award from the Boston Chamber of Commerce, and the 2019 Ray Adams American Neurological Association Award. She received a B.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.D. from Harvard Medical School, and a MSc. in Clinical Epidemiology from Harvard School of Public Health.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases --
--库德科维奇博士是研究和治疗肌萎缩侧索硬化症(ALS)和其他神经系统疾病的先驱--
MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Merit Cudkowicz to its Scientific Advisory Board ("SAB").
佛罗里达州迈阿密海滩,9月2022年10月15日(环球通讯社)--专注于发现、研究和开发治疗中枢神经系统疾病的新型有效疗法的生物技术公司帕西西亚治疗公司(纳斯达克代码:KTTA)(以下简称“帕西西亚”或“公司”)今天宣布任命梅里特·库德科维奇博士为其科学咨询委员会成员。
Dr. Cudkowicz is the Chief of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a pioneer in promoting and devising more efficient methods for the development of new therapies for people with neurological disorders such as ALS and is one of the founders and co-directors of the Northeast ALS (NEALS) Consortium, a group of over 130 clinical sites in the United States and Canada dedicated to performing collaborative academic-led clinical trials in ALS. Dr. Cudkowicz is also the Study Chair and Principal Investigator of the HEALEY ALS Platform Trial, a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
库德科维奇博士是马萨诸塞州综合医院的神经科主任,董事是西恩·M·希利和肌萎缩侧索硬化症中心的肌萎缩侧索硬化症的神经科主任,也是哈佛医学院的朱莉安·多恩神经学教授。作为美国国家医学研究院的成员,Cudkowicz博士一直是推动和设计更有效的方法来为患有ALS等神经疾病的人开发新疗法的先驱,也是东北ALS(Neals)联盟的创始人和联席董事之一,该联盟是一个由美国和加拿大的130多个临床站点组成的团体,致力于在ALS中进行由学术指导的合作临床试验。Cudkowicz博士也是Healey ALS平台试验的研究主席和首席研究员,Healey ALS平台试验是一项永久性的多中心、多方案临床试验,评估用于治疗ALS的研究产品的安全性和有效性。
"Dr. Cudkowicz's achievements in the research and treatment of ALS are extraordinary and second to none, and her collaborative, cross-field methodology has revolutionized ALS clinical trials. Her knowledge, experience, and forward-thinking approach will be a huge asset to Pasithea as we advance our mission of bringing our alpha-5/beta-1 monoclonal antibody to clinical trials in ALS," said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
帕西西亚治疗公司首席执行官蒂亚戈·里斯·马奎斯博士说:“库德科维奇博士在肌萎缩侧索硬化症的研究和治疗方面取得了非凡和首屈一指的成就,她的合作、跨领域的方法论使肌萎缩侧索硬化症的临床试验发生了革命性的变化。她的知识、经验和前瞻性思维方法将是帕西西亚的一笔巨大财富,因为我们将把我们的阿尔法-5/贝塔-1单抗带入肌萎缩侧索硬化症的临床试验。”
"I am honored that my role with the SAB will allow me to work closely with Dr. Steinman and the team at Pasithea on their new program for ALS. Their approach is novel, with preclinical and human post-mortem data supporting a role for alpha-5/beta-1 integrin in the pathophysiology of ALS. The preclinical efficacy data of Pasithea´s monoclonal antibody targeting alpha-5/beta-1 integrin is very encouraging and we will work together to bring this drug to clinical trial for people living with ALS," stated Dr. Cudkowicz.
Cudkowicz博士说:“我很荣幸,我在SAB的工作将使我能够与斯坦曼博士和Pasithea的团队在他们治疗ALS的新计划上密切合作。他们的方法是新颖的,临床前和人类尸检数据支持α-5/β-1整合素在ALS病理生理学中的作用。Pasithea针对α-5/β-1整合素的临床前疗效数据非常令人鼓舞,我们将共同努力,将这种药物带到ALS患者的临床试验中。”
Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award, the 2017 Forbes Norris Award from the International MND Alliance, the 2017 Pinnacle Award from the Boston Chamber of Commerce, and the 2019 Ray Adams American Neurological Association Award. She received a B.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.D. from Harvard Medical School, and a MSc. in Clinical Epidemiology from Harvard School of Public Health.
Cudkowicz博士获得了美国神经科学院2009年度Sheila短文ALS奖、国际MND联盟2017年度福布斯·诺里斯奖、波士顿商会2017年度顶峰奖和2019年Ray Adams美国神经学协会奖。她拥有麻省理工学院的化学工程学士学位、哈佛医学院的医学博士学位和理学硕士学位。哈佛大学公共卫生学院临床流行病学专业。
About Pasithea Therapeutics Corp.
Pasithea治疗公司简介
Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Pasithea治疗公司是一家生物技术公司,专注于发现、研究和开发治疗中枢神经系统(CNS)疾病的新的有效疗法。Pasithea在神经科学和精神药理学领域拥有一支经验丰富的专家团队,正在开发用于治疗精神和神经疾病的新分子实体,包括肌萎缩侧索硬化症(ALS)和多发性硬化症(MS)。Pasithea还专注于通过在诊所和家庭环境中提供静脉注射氯胺酮来满足目前患有精神疾病的患者的需求。
Forward Looking Statements
前瞻性陈述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
本新闻稿包含构成“前瞻性陈述”的陈述。前瞻性陈述受许多条件的制约,其中许多条件不在公司的控制范围之内。虽然公司相信这些前瞻性陈述是合理的,但不应过度依赖任何此类前瞻性陈述,这些前瞻性陈述是基于公司在本新闻稿发布之日所掌握的信息。这些前瞻性陈述是基于当前的估计和假设,会受到各种风险和不确定性的影响,包括但不限于公司提交给美国证券交易委员会的报告中陈述的风险和不确定性。因此,实际结果可能会有很大不同。除法律要求外,本公司不承担在本新闻稿发布之日后因新信息、未来事件或其他原因而更新这些陈述的义务。
Pasithea Therapeutics Corp. Company Contact
Pasithea治疗公司联系人
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
蒂亚戈·里斯·马奎斯博士
首席执行官
电子邮件:tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Pasithea治疗公司投资者关系
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
丽莎·M·威尔逊
现场通信公司
T: 212-452-2793
电子邮箱:lwilson@insiteconi.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧